JAZZ Q4 2021 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$897M+34.7% YoY

Gross Profit

$761M84.8% margin

Operating Income

$49M5.5% margin

Net Income

-$35M-3.9% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

$178M

Free Cash Flow

$168M

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$12.3B

Total Liabilities

$8.3B

Stockholders' Equity

$4.0B

Cash & Equivalents

$591M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$897M	$666M	+34.7%
Gross Profit	$761M	$615M	+23.6%
Operating Income	$49M	$173M	-71.5%
Net Income	-$35M	$133M	-126.5%

Revenue Segments

Xyrem

$289M33%

Epidiolex/Epidyolex

$194M22%

Xywav

$183M21%

Rylaze/Enrylaze

$65M7%

Zepzelca

$65M7%

Defitelio/Defibrotide

$43M5%

Vyxeos

$35M4%

Sativex

$5M1%

Other Products

$1M0%

Geographic Segments

UNITED STATES

$824M92%

Europe

$65M7%

Other Countries

$8M1%